Filter Results:
(624)
Show Results For
- All HBS Web
(624)
- People (2)
- News (57)
- Research (449)
- Events (2)
- Multimedia (8)
- Faculty Publications (395)
Show Results For
- All HBS Web
(624)
- People (2)
- News (57)
- Research (449)
- Events (2)
- Multimedia (8)
- Faculty Publications (395)
- February 1992
- Case
U.S. Biotechnology Industry in 1987 (Abridged)
By: Dorothy Leonard-Barton and Alistair D. Williamson
Leonard-Barton, Dorothy, and Alistair D. Williamson. "U.S. Biotechnology Industry in 1987 (Abridged)." Harvard Business School Case 792-077, February 1992.
- 31 May 2024
MS/MBA Biotechnology Life Sciences Information Session
Join us for a virtual event with program faculty and Admissions staff to learn more about Harvard's MS/MBA Biotechnology: Life Sciences joint degree. View Details
- October 1988 (Revised November 1988)
- Case
Du Pont: Biotechnology in Agricultural Products
By: Ray A. Goldberg
Goldberg, Ray A. "Du Pont: Biotechnology in Agricultural Products." Harvard Business School Case 589-058, October 1988. (Revised November 1988.)
- 09 Jul 2019
- Blog Post
Solving the Complexities of the Biotechnology Industry
Biotechnology is a complex industry which combines applied science & engineering and applied business practices with life science. It is the most multi-faceted industry segment there is because it is ultimately focused on the most... View Details
- 31 May 2024
- Video
Harvard MS/MBA Biotechnology Life Sciences Info Session
- 31 May 2024
- Video
Harvard MS/MBA Biotechnology Life Sciences Info Session
- March 1992 (Revised June 2005)
- Teaching Note
Monsanto's March into Biotechnology (A), Teaching Note
By: Dorothy Leonard-Barton and Alistair D. Williamson
Teaching Note for (9-690-009). View Details
Keywords: Biotechnology Industry
- 1988
- Chapter
Joint Ventures and Collaboration in the Biotechnology Industry
By: Gary P. Pisano, W. Shan and David Teece
- January 2000
- Article
The Tragedy of the Commoners: Biotechnology and its Publics
By: Arthur A. Daemmrich
Keywords: Biotechnology Industry
Daemmrich, Arthur A. "The Tragedy of the Commoners: Biotechnology and its Publics." Nature Biotechnology 18, no. 1 (January 2000): 2–4.
- March 2011
- Case
MorphoSys AG: The Evolution of a Biotechnology Business Model
By: Gary P. Pisano, Ryan Johnson and Carin-Isabel Knoop
In the biotech world, the 18-year-old Munich-based company MorphoSys was a rarity: it was profitable. The company achieved this profitability not by developing and selling its own drugs, but by licensing access to its proprietary library of human antibodies. Recently,... View Details
Keywords: Business Model; Profit; Intellectual Property; Rights; Risk Management; Digital Platforms; Product Development; Business and Shareholder Relations; Vertical Integration; Biotechnology Industry; Munich
Pisano, Gary P., Ryan Johnson, and Carin-Isabel Knoop. "MorphoSys AG: The Evolution of a Biotechnology Business Model." Harvard Business School Case 611-046, March 2011.
- Article
Do Equity Financing Cycles Matter?: Evidence from Biotechnology Alliances
By: Josh Lerner, Hilary Shane and Alexander Tsai
Lerner, Josh, Hilary Shane, and Alexander Tsai. "Do Equity Financing Cycles Matter?: Evidence from Biotechnology Alliances." Journal of Financial Economics 67, no. 3 (March 2003): 411–446. (Earlier versions distributed as HBS Working Paper No. 00-038 and NBER Working Paper No. 7464.)
- Article
Using Equity Participation to Support Exchange: Evidence from the Biotechnology Industry
By: Gary P. Pisano
Pisano, Gary P. "Using Equity Participation to Support Exchange: Evidence from the Biotechnology Industry." Journal of Law, Economics & Organization 5, no. 1 (Spring 1989): 109–126.
- February 2012
- Article
A 'Core Periphery' Framework to Navigate Emerging Market Governments—Qualitative Evidence from a Biotechnology Multinational
By: Prithwiraj Choudhury, James Geraghty and Tarun Khanna
We build on the emerging literature of influence-based models to study how multinational firms can navigate host governments. Our "core-periphery" framework posits that the actions that an MNC takes with actors in what we call the "periphery"—comprised of state,... View Details
Keywords: Emerging Markets; Multinational Firms and Management; Business and Government Relations; Power and Influence; Framework; Biotechnology Industry; Massachusetts; Brazil; China; Costa Rica; France; India
Choudhury, Prithwiraj, James Geraghty, and Tarun Khanna. "A 'Core Periphery' Framework to Navigate Emerging Market Governments—Qualitative Evidence from a Biotechnology Multinational." Global Strategy Journal 2, no. 1 (February 2012): 71–87.
- September 2020
- Case
Minerva 2010: Turbulent Times
By: John R. Wells and Benjamin Weinstock
In 2010, amid a flurry of new discoveries, Cynthia Bamdad, founder and CEO of Minerva Biotechnologies Corporation (Minerva), raised $6.6 million to test her new cancer drugs in mice. It had been more than 6 years since she had announced that she and her small team at... View Details
Wells, John R., and Benjamin Weinstock. "Minerva 2010: Turbulent Times." Harvard Business School Case 721-390, September 2020.
- Article
The Control of Technology Alliances: An Empirical Analysis of the Biotechnology Industry
By: Josh Lerner and Robert P. Merges
Lerner, Josh, and Robert P. Merges. "The Control of Technology Alliances: An Empirical Analysis of the Biotechnology Industry." Journal of Industrial Economics 46, no. 2 (June 1998): 125–156. (Special Symposium "Inside the Pin Factory": Empirical Studies Augmented by Manager Interviews.)
- Article
The Governance of Innovation: Vertical Integration and Collaborative Arrangements in the Biotechnology Industry
By: Gary P. Pisano
Pisano, Gary P. "The Governance of Innovation: Vertical Integration and Collaborative Arrangements in the Biotechnology Industry." Research Policy 20, no. 3 (June 1991): 237–249.